CU20130079A7 - Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer - Google Patents

Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer

Info

Publication number
CU20130079A7
CU20130079A7 CU2013000079A CU20130079A CU20130079A7 CU 20130079 A7 CU20130079 A7 CU 20130079A7 CU 2013000079 A CU2013000079 A CU 2013000079A CU 20130079 A CU20130079 A CU 20130079A CU 20130079 A7 CU20130079 A7 CU 20130079A7
Authority
CU
Cuba
Prior art keywords
modified
cells
treat cancer
receiver
chemeric
Prior art date
Application number
CU2013000079A
Other languages
English (en)
Inventor
Carl H June
Bruce L Levine
David L Porter
Michael D Kalos
Michael C Milone
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/064191 external-priority patent/WO2012079000A1/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of CU20130079A7 publication Critical patent/CU20130079A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención provee composiciones y métodos para tratar cáncer en un humano; la invención se refiere a la administración de una célula T genéticamente modificada para expresar un CAR en donde el CAR comprende un dominio de unión a antígeno, un dominio de transmembrana, una región de señalización co- estimulante, y un dominio de señalización de CD3 zeta.
CU2013000079A 2011-06-29 2013-06-10 Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer CU20130079A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502649P 2011-06-29 2011-06-29
PCT/US2011/064191 WO2012079000A1 (en) 2010-12-09 2011-12-09 Use of chimeric antigen receptor-modified t cells to treat cancer

Publications (1)

Publication Number Publication Date
CU20130079A7 true CU20130079A7 (es) 2013-09-27

Family

ID=52395350

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000079A CU20130079A7 (es) 2011-06-29 2013-06-10 Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer

Country Status (3)

Country Link
CU (1) CU20130079A7 (es)
EA (1) EA202090716A1 (es)
TN (1) TN2013000246A1 (es)

Also Published As

Publication number Publication date
EA202090716A1 (ru) 2021-03-31
TN2013000246A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
ECSP13012739A (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer
MX2018009820A (es) Uso de cart19 para eliminar celulas b normales para inducir tolerancia.
IN2014DN07414A (es)
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
EP4275699A3 (en) Use of the cd2 signaling domain in second-generation chimeric antigen receptors
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
NZ743310A (en) Method and compositions for cellular immunotherapy
CY1120707T1 (el) Anti-cd28 εξανθρωπισμενα αντισωματα
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
NZ604510A (en) Dilutable biocidal compositions and methods of use
IN2014MN01879A (es)
WO2014055442A3 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
EP3467101A3 (en) Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
CU20130079A7 (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
AR123070A2 (es) Anticuerpos anti-il-23